



Posaconazole vs voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies.



Reem Almutairy^{1a}, Mansoor A. Khan^{1a}, Majed A. Alshamrani^{1a}, Hassan Marhabi^{1b}, Mohammed Aseeri^{1a}, Doaa Naeem^{1a}

1- King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, ^a Pharmaceutical care services, ^b Department of medicine, infectious disease section.

Both posaconazole & voriconazole have **comparable efficacy and safety** in the prevention of IFD in AML and MDS receiving chemotherapy but **voriconazole is more cost effective.**



Take a picture to download the full paper

Background

- The incidence of Invasive Fungal Diseases (IFDs) in patients with hematologic malignancies is increasing.
- Both Posaconazole and voriconazole has been recommended by guidelines with different levels of recommendations.
- Data on a direct comparison between Posaconazole delayed-release tablets (DR) and Voriconazole for IFD prophylaxis are lacking.

Aim and objectives

Our aim was to compare the efficacy and safety of the fungal prophylaxis in AML/MDS patients at Princess Nourah Oncology Center (PNOC), Jeddah. Saudi Arabia

Primary Objective:

- Identify the rate of breakthrough IFD

Secondary objective:

- Assess the proportion of adverse events
- Identify the drug acquisition cost

Method

Retrospective chart review study for eligible patients from January 2017 to February 2019

Inclusion/Exclusion Criteria

- ✓ Age ≥ 14 years.
- ✓ AML /MDS patient undergoing intensive induction/consolidation chemotherapy.
- ✓ Received delayed-release posaconazole tablets or voriconazole as antifungal prophylaxis.
- ✗ Probable and proven invasive fungal disease before starting chemotherapy and antifungal prophylaxis.

Patient characteristic

Total number of patients (48)
Total number of chemo cycles (130)

Characteristic	Voriconazole (80)	Posaconazole (50)
Age, years	47 (24-71)	
Weight, Kg	68 (24-103)	
Female, n (%)	26 (54)	
Type of chemo, n (%)		
(7+3)	25 (31)	8 (16)
HIDAC	39 (48)	28 (56)
FLAG-IDA	7 (9)	4 (8)
FLAG	1 (1)	1 (2)
Azacytidine	3 (4)	3 (6)
5+2	3 (4)	1 (2)
IDAC&SORAFINIB	2 (3)	5 (10)
Median days of prophylaxis (range)	19 (7- 31)	20 (12- 28)

Results

Incidence of IFD

IFD Classification

Primary Outcome




	Probable	Possible
Voriconazole	4	1
Posaconazole	2	2


All values are expressed as median (IQR) unless otherwise noted.

Secondary Outcomes

Rate of discontinuation due to adverse events



Antifungal prophylaxis acquisition cost



Total cost of antifungal prophylaxis for 15 days in 130 cycles (48 AML/MDS patients)